Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
WINTER SPRINGS, Fla., Jan. 28, 2016 -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $10 million of the Company’s common stock through January 28, 2017.
The Company intends to use cash on hand, investments and cash generated from operations to fund the share repurchase program. As of December 31, 2015, the Company had cash, cash equivalents and investments of approximately $27 million.
The timing and amount of the repurchases will be subject to applicable legal requirements including federal and state securities laws. Purchases will be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. Any repurchased shares will be available for general corporate purposes.
About IRADIMED CORPORATION
IRADIMED CORPORATION is the only known provider of non-magnetic intravenous (“IV”) infusion pump systems that are specifically designed to be safe for use during magnetic resonance imaging (“MRI”) procedures. We were the first to develop an infusion delivery system that neutralizes the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency (“RF”) interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our MRidium MRI compatible IV infusion pump system has been designed with a patented non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated in order to remain immobile during an MRI scan.
Media Contact: Chris Scott Chief Financial Officer IRADIMED CORPORATION (407) 677-8022 [email protected]
